MIGUEL JOSÉ
MARTÍN JIMÉNEZ
Catedrático de universidad
David Geffen School of Medicine at UCLA
Los Ángeles, Estados UnidosPublikationen in Zusammenarbeit mit Forschern von David Geffen School of Medicine at UCLA (22)
2023
-
Tumor biomarkers and efficacy in patients treated with trastuzumab emtansine + pertuzumab versus standard of care in HER2-positive early breast cancer: an open-label, phase III study (KRISTINE)
Breast cancer research : BCR, Vol. 25, Núm. 1, pp. 2
2022
-
Comparative biomarker analysis of PALOMA-2/3 trials for palbociclib
npj Precision Oncology, Vol. 6, Núm. 1
-
Determinants of Response to Talazoparib in Patients with HER2-Negative, Germline BRCA1/2-Mutated Breast Cancer
Clinical Cancer Research, Vol. 28, Núm. 7, pp. 1383-1390
2021
-
Corrigendum to ‘Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival’: [Annals of Oncology Volume 32, Issue 8, August 2021, Pages 1015-1024](S0923753421015532)(10.1016/j.annonc.2021.05.353)
Annals of Oncology
-
Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival
Annals of Oncology, Vol. 32, Núm. 8, pp. 1015-1024
2020
-
Adjuvant denosumab in early breast cancer (D-CARE): an international, multicentre, randomised, controlled, phase 3 trial
The Lancet Oncology, Vol. 21, Núm. 1, pp. 60-72
-
Biomarker analyses of response to cyclin-dependent kinase 4/6 inhibition and endocrine therapy in women with treatment-naïve metastatic breast cancer
Clinical Cancer Research, Vol. 26, Núm. 1, pp. 110-121
-
Oncological care organisation during COVID-19 outbreak
ESMO Open, Vol. 5, Núm. 4
-
Outcomes in clinically relevant patient subgroups from the EMBRACA study: Talazoparib vs physician's choice standard-of-care chemotherapy
JNCI Cancer Spectrum, Vol. 4, Núm. 1
-
Overall survival with ribociclib plus fulvestrant in advanced breast cancer
New England Journal of Medicine, Vol. 382, Núm. 6, pp. 514-524
-
Progression-free Survival Outcome Is Independent of Objective Response in Patients With Estrogen Receptor-positive, Human Epidermal Growth Factor Receptor 2-negative Advanced Breast Cancer Treated With Palbociclib Plus Letrozole Compared With Letrozole: Analysis From PALOMA-2
Clinical Breast Cancer, Vol. 20, Núm. 2, pp. e173-e180
2019
-
Assessment of ERBB2 / HER2 Status in HER2 -Equivocal Breast Cancers by FISH and 2013/2014 ASCO-CAP Guidelines
JAMA Oncology, Vol. 5, Núm. 3, pp. 366-375
-
Neoadjuvant trastuzumab emtansine and pertuzumab in human epidermal growth factor receptor 2–positive breast cancer: Three-year outcomes from the phase III KristinE study
Journal of Clinical Oncology
2018
-
Clinical considerations of the role of palbociclib in the management of advanced breast cancer patients with and without visceral metastases
Annals of Oncology, Vol. 29, Núm. 3, pp. 669-680
-
Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial
The Lancet Oncology, Vol. 19, Núm. 1, pp. 115-126
2016
-
HER2 gene amplification testing by fluorescent in situ hybridization (FISH): Comparison of the ASCO-College of American Pathologists guidelines with FISH scores used for enrollment in Breast Cancer International Research Group clinical trials
Journal of Clinical Oncology, Vol. 34, Núm. 29, pp. 3518-3528
-
Palbociclib and letrozole in advanced breast cancer
New England Journal of Medicine, Vol. 375, Núm. 20, pp. 1925-1936
2015
-
PTEN loss is associated with worse outcome in HER2-Amplified breast cancer patients but is not associated with trastuzumab resistance
Clinical Cancer Research, Vol. 21, Núm. 9, pp. 2065-2074
2013
2011
-
Adjuvant trastuzumab in HER2-positive breast cancer.
The New England journal of medicine, Vol. 365, Núm. 14, pp. 1273-1283